Engineered nanoparticles for drug delivery in cancer therapy
- PMID:25294565
- DOI: 10.1002/anie.201403036
Engineered nanoparticles for drug delivery in cancer therapy
Abstract
In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues associated with conventional therapeutic agents, including their poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Over the past several decades, remarkable progress has been made in the development and application of engineered nanoparticles to treat cancer more effectively. For example, therapeutic agents have been integrated with nanoparticles engineered with optimal sizes, shapes, and surface properties to increase their solubility, prolong their circulation half-life, improve their biodistribution, and reduce their immunogenicity. Nanoparticles and their payloads have also been favorably delivered into tumors by taking advantage of the pathophysiological conditions, such as the enhanced permeability and retention effect, and the spatial variations in the pH value. Additionally, targeting ligands (e.g., small organic molecules, peptides, antibodies, and nucleic acids) have been added to the surface of nanoparticles to specifically target cancerous cells through selective binding to the receptors overexpressed on their surface. Furthermore, it has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be delivered through the same carrier to enable combination therapy with a potential to overcome multidrug resistance, and real-time readout on the treatment efficacy. It is anticipated that precisely engineered nanoparticles will emerge as the next-generation platform for cancer therapy and many other biomedical applications.
Keywords: cancer therapy; controlled release; drug delivery; nanomedicine; nanoparticles.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
- Role of integrated cancer nanomedicine in overcoming drug resistance.Iyer AK, Singh A, Ganta S, Amiji MM.Iyer AK, et al.Adv Drug Deliv Rev. 2013 Nov;65(13-14):1784-802. doi: 10.1016/j.addr.2013.07.012. Epub 2013 Jul 21.Adv Drug Deliv Rev. 2013.PMID:23880506Review.
- Anticancer drug delivery with nanoparticles.Conti M, Tazzari V, Baccini C, Pertici G, Serino LP, De Giorgi U.Conti M, et al.In Vivo. 2006 Nov-Dec;20(6A):697-701.In Vivo. 2006.PMID:17203748Review.
- Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy.Du JZ, Mao CQ, Yuan YY, Yang XZ, Wang J.Du JZ, et al.Biotechnol Adv. 2014 Jul-Aug;32(4):789-803. doi: 10.1016/j.biotechadv.2013.08.002. Epub 2013 Aug 7.Biotechnol Adv. 2014.PMID:23933109Review.
- pH-sensitive nano-systems for drug delivery in cancer therapy.Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A, Liang XJ.Liu J, et al.Biotechnol Adv. 2014 Jul-Aug;32(4):693-710. doi: 10.1016/j.biotechadv.2013.11.009. Epub 2013 Dec 3.Biotechnol Adv. 2014.PMID:24309541Review.
- Design considerations for nanotherapeutics in oncology.Stylianopoulos T, Jain RK.Stylianopoulos T, et al.Nanomedicine. 2015 Nov;11(8):1893-907. doi: 10.1016/j.nano.2015.07.015. Epub 2015 Aug 15.Nanomedicine. 2015.PMID:26282377Free PMC article.Review.
Cited by
- Multifunctional bioactive glass nanoparticles: surface-interface decoration and biomedical applications.Chen M, Wang Y, Yuan P, Wang L, Li X, Lei B.Chen M, et al.Regen Biomater. 2024 Sep 6;11:rbae110. doi: 10.1093/rb/rbae110. eCollection 2024.Regen Biomater. 2024.PMID:39323748Free PMC article.Review.
- Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms.Sun Y, Davis E.Sun Y, et al.Nanomaterials (Basel). 2021 Mar 16;11(3):746. doi: 10.3390/nano11030746.Nanomaterials (Basel). 2021.PMID:33809633Free PMC article.Review.
- Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.Schütz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck JP.Schütz C, et al.Oncotarget. 2016 Oct 18;7(42):68503-68512. doi: 10.18632/oncotarget.11785.Oncotarget. 2016.PMID:27602488Free PMC article.
- Advances in Lipid and Metal Nanoparticles for Antimicrobial Peptide Delivery.Makowski M, Silva ÍC, Pais do Amaral C, Gonçalves S, Santos NC.Makowski M, et al.Pharmaceutics. 2019 Nov 8;11(11):588. doi: 10.3390/pharmaceutics11110588.Pharmaceutics. 2019.PMID:31717337Free PMC article.Review.
- Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases.Li H, Yang YG, Sun T.Li H, et al.Front Bioeng Biotechnol. 2022 Apr 6;10:889291. doi: 10.3389/fbioe.2022.889291. eCollection 2022.Front Bioeng Biotechnol. 2022.PMID:35464732Free PMC article.Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous